Mabwell (Shanghai) Bioscience Co. Ltd. A

The Sci-Tech Innovation Board Medical ETF Huaxia rose 0.83%, heading for a sixth consecutive gain, with the latest price at 1.1 yuan. The Shanghai Sci-Tech Innovation Board Biomedical Index advanced 0.89%, with constituent Hotgen Biotech surging 10.60% and Mabwell Biotech climbing 9.42%. The National Medical Products Administration plans to include eligible cell and gene therapy drugs in a 30-day review channel for innovative drug clinical trial approvals, a policy that is catalyzing a valuation recovery for innovative drugs. The ETF has seen net inflows for six consecutive days, attracting a total of 61.04 million yuan.

The innovative drug sector opened lower on July 6 before climbing higher in choppy trade. Shouyao Holdings surged by the 20 percent daily limit, Maiwei Bio and Shutaishen jumped over 10 percent, BeiGene rose more than 6 percent, and Asymchem and Hengrui Medicine gained over 4 percent. On the news front, the General Office of the National Medical Products Administration recently sought public comments on a draft notice regarding optimizing the review and approval of cell and gene therapy drugs. The draft mentions supporting clinically driven innovation in cell and gene therapy drug development, focusing on key areas such as malignant tumors and rare diseases, encouraging global simultaneous development, and including eligible cell and gene therapy drugs in a 30-day review and approval channel for innovative drug clinical trials. A research note from Orient Securities noted that Chinese companies have recently made gradual breakthroughs in frontier fields such as cell therapy and AI-driven drug discovery. Several innovative drug makers have seen their core products enter the harvest stage, while medical insurance access, commercial insurance coverage, and cost ratio optimization are jointly driving continuous profit improvement.